Latanoprostene bunod is a Small Molecule owned by Bausch Health Companies, and is involved in 11 clinical trials, of which 10 were completed, and 1 is ongoing.

Latanoprostene bunod is a nitric oxide-donating prostaglandin F2-alpha analog, which lowers intraocular pressure through a dual mechanism of action. Selective FP prostanoid receptor agonist believed to reduce IOP by increasing uveoscleral outflow. The drug candidate is expected to decrease the intraocular pressure by nitrate production, and finally NO release. The increase of nitric oxide makes vasodilatation the final effect being the decrease of intraocular pressure and on the other hand the contra-apoptotic effect giving neuroprotection. Nitric oxide (NO) modulates endothelial integrity and exerts anti-apoptotic activity.

The revenue for Latanoprostene bunod is expected to reach a total of $2.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Latanoprostene bunod NPV Report.

Latanoprostene bunod was originated by NicOx and is currently owned by Bausch Health Companies.

Latanoprostene bunod Overview

Latanoprostene bunod (Vyzulta) is a prostaglandin analog acts as an antiglaucoma agent. It is fromualted as drops-solution for ophthalmic route of administration. Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Vyzulta is under development for the treatment of open angle glaucoma or ocular hypertension (in Japan).

Bausch Health Companies Overview

Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.

The company reported revenues of (US Dollars) US$8,434 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 4.6%, compared to an operating margin of 7.7% in FY2020. The net loss of the company was US$948 million in FY2021, compared to a net loss of US$560 million in FY2020. The company reported revenues of US$2,046 million for the third quarter ended September 2022, an increase of 4% over the previous quarter.

Quick View – Latanoprostene bunod

Report Segments
  • Innovator (NME)
Drug Name
  • Latanoprostene bunod
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.